Team

HemaFlo Therapeutics Team

Michael Martino

President and CEO

Mike has a track record of building and leading multidisciplinary teams, developing focused strategies, negotiating deals and raising capital in the private and public sectors. From November 2011 to November 2014 he was President, CEO and a member of the board of Ambit Biosciences, where he built and lead the team that: accelerated the development of the company’s lead drug from Phase 2 to Phase 3, completed a successful IPO in May 2013, and closed a merger with Daiichi Sankyo in November 2014. Prior to Ambit, Mike was a co-founder and CEO of Arzeda, a synthetic biology company that he helped spin-out of the University of Washington. From 1998 to 2007 Mike was President, CEO and a member of the board of Sonus Pharmaceuticals, a publicly-traded company, where he refocused the company on oncology drugs, accelerated the development of the company’s lead drug from preclinical studies to the completion of a pivotal Phase 3 study in five years, raised more than $100 million in new capital and ultimately engineered the company’s reverse merger with Oncogenex Technologies. Mike began his career with Mallinckrodt in 1983 where, over 15-years, he progressed through staff positions in planning, business development, marketing and general management, including VP & General Manager of Mallinckrodt’s global nuclear medicine business. Mike has a BBA from Roanoke College, and a MBA from Virginia Tech. He sits on the board of Arzeda, and is a prior Chair of the Board of the Washington Biotechnology & Biomedical Association (WBBA) and of the Board of Trustees of Cascadia Community College, all in Seattle.


Dale Peterson, PhD

CSO

With a talent for forming multidisciplinary teams to commercialize challenging, valuable new medical products, Dale has successfully commercialized 19 medical devices including combination and PMA products such as the first clinical cell culture system (Stericell™), the first clinical stem cell isolation system (CellPro’s CePrate), the first automated food pathogen identification instrument (RiboPrinter™), BioFiber™ products made from a new resorbable polymer, and the first microvascular-based products. He holds 27 issued US patents in 10 disciplines. Dale has helped start-up four companies (CellPro, Intent, MicroVascular Tissues, HemaFlo Therapeutics), three successful joint ventures (Stericell, DePuy-Dupont Orthopedics, Qualicon), and experienced three IPO’s (CellPro, DePuy, Tornier). He has also worked at DuPont, Boehringer-Mannheim, J&J, Tornier, and consulted for firms in fields such as cardiovascular devices, stem cells, and tissue replacements. In addition to R&D roles, he led the Tissue Engineering initiative for Ethicon (NBD) and evaluated hundreds of businesses for the Vertical Group. He earned a BS degree in chemical engineering summa cum laude from Brigham Young University, and a PhD in chemical engineering from the University of Washington.


Joseph Bonventre, MD/PhD

SAB

Dr. Bonventre holds appointments as Chief of both the Renal Division and the Founding Chief of the Biomedical Engineering Division at a large academic medical center. He runs a large, productive research lab focused on kidney injury, repair, and signal transduction and has over 300 peer-reviewed publications and 150 invited book chapters and reviews. He is past president of the American Society for Nephrology, received two MERIT awards from the NIH, and has been elected to the American Society of Clinical Investigation, the Association of American Physicians, and the American Institute for Medical and Biological Engineering. He served as director of the Harvard-MIT Health Sciences and Technology program for 10 years and was the founding head of the Kidney Group and is now on the Executive Committee of the Harvard Stem Cell Institute. He served on the Board of Directors of AMAG Pharmaceuticals and has been a Founding Board of Directors member of the National Space Biology Research Institute. He is also the co-founder of two companies and an advisor to a number of other pharmaceutical and biotechnology companies.

In addition to his BS with distinction in Engineering Physics from Cornell, Dr. Bonventre holds MD and PhD degrees from Harvard University and honorary degrees from Mt. Saint Mary’s College and from the Norwegian Institute of Science and Technology.

HemaFlo Therapeutics © 2016